title: Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in Type II diabetic patients suffering from microalbuminuria.
authors.forename: S
authors.initials: S
authors.lastname: Gasic
authors.forename: O F
authors.initials: OF
authors.lastname: Wagner
authors.forename: P
authors.initials: P
authors.lastname: Fasching
authors.forename: C
authors.initials: C
authors.lastname: Ludwig
authors.forename: M
authors.initials: M
authors.lastname: Veitl
authors.forename: S
authors.initials: S
authors.lastname: Kapiotis
authors.forename: B
authors.initials: B
authors.lastname: Jilma
mesh_terms: D000419:Albuminuria / Q000097:blood*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D005260:Female; D017328:Fosinopril / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019010:Vascular Cell Adhesion Molecule-1 / Q000097:blood*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D019010:Vascular Cell Adhesion Molecule-1; D017328:Fosinopril